NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $5.42 -0.02 (-0.28%) As of 03:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.23▼$5.4550-Day Range$4.93▼$6.5852-Week Range$4.27▼$9.94Volume356,599 shsAverage Volume1.58 million shsMarket Capitalization$327.39 millionP/E RatioN/ADividend YieldN/APrice Target$13.70Consensus RatingModerate Buy Company Overview Vanda Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review. Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24-hour sleep-wake disorder in totally blind individuals and for night-time sleep disturbances in Smith–Magenis syndrome. The company also markets Firdapse (amifampridine), indicated for the treatment of Lambert–Eaton myasthenic syndrome. Both products exemplify Vanda’s expertise in rare and orphan diseases and reflect its ability to bring targeted therapies from concept to market. Beyond its approved products, Vanda maintains a diversified clinical pipeline that includes VNP01 for the treatment of manic episodes in bipolar I or II disorder and other investigational compounds addressing depressive disorders, Parkinson’s disease, and additional CNS indications. The company leverages strategic partnerships and in-house expertise to advance these candidates through Phase II and III trials, with the goal of expanding its therapeutic portfolio and geographic reach. Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates primarily in the United States and holds regulatory authorizations in Europe and other international markets. Since January 2014, Dr. Mihael Polymeropoulos has served as President and Chief Executive Officer, guiding the company through successful product launches and global expansion efforts. Vanda’s leadership team combines clinical, regulatory, and commercial experience to support its strategic growth in the CNS and rare disease arenas.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreVNDA MarketRank™: Vanda Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 354th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVanda Pharmaceuticals has a consensus price target of $13.70, representing about 154.4% upside from its current price of $5.39.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($3.00) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.20% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 6.16.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 3.31%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.29 News SentimentVanda Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 9 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Stock News HeadlinesVanda Pharmaceuticals Announces Participation at September 2026 Investor ConferencesSeptember 2, 2026 | prnewswire.comVanda Pharmaceuticals Inc. (VNDA)August 25, 2026 | finance.yahoo.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.September 8 at 1:00 AM | Decentralized Masters (Ad)Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European CommissionAugust 24, 2026 | prnewswire.comNEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.August 22, 2026 | prnewswire.comVanda (VNDA) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comVanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comVanda: Q2 Earnings SnapshotAugust 5, 2026 | chron.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of 2026. Since then, VNDA stock has decreased by 38.9% and is now trading at $5.3850. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.46. The biopharmaceutical company earned $50.53 million during the quarter, compared to analysts' expectations of $61.93 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 49.81% and a negative net margin of 127.41%. Read the conference call transcript. Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' top institutional investors include BlackRock Inc. (12.73%), AIGH Capital Management LLC (3.40%), Ieq Capital LLC (0.47%) and Monaco Asset Management SAM (0.37%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Gunther Birznieks, Kevin Patrick Moran, Timothy Williams, Joakim Wijkstrom and Stephen Ray Mitchell. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/05/2026Today9/08/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VNDA's financial health is in the Red zone, according to TradeSmith. VNDA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$13.70 High Price Target$20.00 Low Price Target$7.50 Potential Upside/Downside+153.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.47 million Net Margins-127.41% Pretax Margin-82.14% Return on Equity-49.81% Return on Assets-33.29% Debt Debt-to-Equity Ratio0.01 Current Ratio1.61 Quick Ratio1.60 Sales & Book Value Annual Sales$216.10 million Price / Sales1.51 Cash FlowN/A Price / Cash FlowN/A Book Value$5.54 per share Price / Book0.98Miscellaneous Outstanding Shares60,460,000Free Float53,993,000Market Cap$327.39 million OptionableOptionable Beta0.64 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:VNDA) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis weekend trading strategy could change your MondaysEvery Monday, trader Tim Sykes opens his account to potential profits as high as $8,780, $9,177, even $16,000....Tim Sykes | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe Closest Thing to a Virtual AI Monopoly Wall Street Is IgnoringA little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...Stansberry Research | SponsoredThe buyers of US debt are vanishing [where the money's going]$9 trillion in US government debt must be rolled over in the next 12 months. Foreign central banks in China, J...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts